Pharmacological treatment for generalized anxiety disorder in adults: an update
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Modest response and remission rates for the selective serotonin reuptake inhibitors and the serotonin-norepinephrine reuptake inhibitors, coupled with mounting evidence that the tolerability of the antidepressants (ADs) may have been overstated in the literature, has contributed to changes in prescribing patterns for generalized anxiety disorder (GAD). New interest in the absence of evidence that supports these standard therapies as superior to benzodiazepines stimulated a review of the literature. AREAS COVERED: A literature search was conducted in the MedLine database with search terms 'generalized anxiety disorder' and 'treatment' for purposes of including relevant literature related to pharmacologic treatment of GAD. Aside from a review of pivotal literature, the authors also included newer studies that evaluated novel drug treatments. Last, the database was searched for benzodiazepine comparisons to standard therapy secondary to concerns that such literature is sparse. The review of newer modalities and the decision to include related literature was also based on the strength of the evidence and the status of their approval for the treatment of GAD. EXPERT OPINION: Although ADs remain the most frequently prescribed medications for GAD, alternative and off-label therapies such as pregabalin, the atypical antipsychotics and vortioxetine are garnering interest. Based on the evidence available to us, it is our recommendation that along with the ADs, benzodiazepines be considered a possible first-line therapy in eligible patients based on the discretion and clinical judgment of the treating physician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“It is estimated that 90% of patients with GAD also have at least one additional comorbid psychiatric diagnosis, most commonly major depressive disorder (61%) [9-11].”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Carleton, R. N. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.82 · Cited by 665 · cited 1×
“This may propagate patterns of reinforcement during which patients anticipate a consequence and develop avoidance behaviors in response [7].”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“The risk and extent of weight gain varies within this class, as some compounds promote weight gain and some are considered weight-neutral [43].”
BackgroundBandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress
Ravindran, L. N., & Stein, M. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06218blu · Cited by 317 · cited 1×
“Drug classes that were experimental for the treatment of GAD 10 years ago have risen to first-line options and newer, novel drug products are now beginning to amass a litany of literature that serves as an evidence base for clinical practice [26].”
BackgroundAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 1×
“5 and 10 mg/day to placebo and found that there was no meaningful difference among any of the study arms [99-102].”
BackgroundBenzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249 · cited 1×
“Their rapid onset of effect and good tolerability make them conducive to alleviating anxious symptoms when immediate anxiolytic effects are necessary [58].”
BackgroundTeff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195 · cited 3×
“There is evidence to suggest that AAPs influence glucose sensitivity and induce insulin resistance even after a single dose [24,115].”
BackgroundSelf-citation
Cited by
Stein, M. B., & Sareen, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1502514 · Cited by 314
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Of note, numerous specialists have voiced the opinion that benzodiazepines can be a reasonable option for certain patients, such as those at a low risk for substance abuse, when other treatments are contraindicated or proven ineffective, so long as they are administered with consistent, close monitoring [58,59].”
BackgroundBenzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Mao, J. J., Xie, S. X., Keefe, J. R., Soeller, I., Li, Q. S., & Amsterdam, J. D. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.10.012 · Cited by 161
“Current psychopharmacological treatments have both limited efficacy and substantial side effects (Mitte et al., 2005; Reinhold and Rickels, 2015), and many patients self-medicate with herbal supplements to alleviate chronic anxiety (McIntyre et al., 2015).”
BackgroundInfluentialGomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
“evidence and in accordance with other recent expert opinions [4],”
BackgroundResult
Metadata
- Authors
- Reinhold, J. A., & Rickels, K.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2015-07-09
- Volume
- 16
- Issue
- 11
- Pages
- 1669-1681
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1854968879
- Cited by
- 82
- References
- 23
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological treatment for generalized anxiety disorder in adults: an update. https://app.cochat.ai/papers/10.1517/14656566.2015.1059424
- The paper
- Reinhold, J. A., & Rickels, K. (2015). Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1059424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.